Metildigoxin


Full Prescribing Info
Dosage/Direction for Use

Oral
Cardiac arrhythmias
Adult: 100-600 mcg daily, depending upon desired digitalisation (usually performed over 2-4 days); larger doses are given in divided doses.
Elderly: Dose reduction may be required.
Renal impairment: Dialysis: Initially, 30-50% of the usual dose.
CrCl (ml/min)Dosage Recommendation
<50per 1.48 m2: Dose reduction may be needed.


Oral
Heart failure
Adult: 100-600 mcg daily, depending upon desired digitalisation (usually performed over 2-4 days); larger doses are given in divided doses.
Elderly: Dose reduction may be required.
Renal impairment: Dialysis: Initially, 30-50% of the usual dose.
CrCl (ml/min)Dosage Recommendation
<50per 1.48 m2: Dose reduction may be needed.


Intravenous
Cardiac arrhythmias
Adult: 100-600 mcg daily, depending upon desired digitalisation (usually performed over 2-4 days); larger doses are given in divided doses. Maintenance: Continue with 50-300 mcg daily by mouth in divided doses.
Elderly: Dose reduction may be required.
Renal impairment: Dialysis: Initially, 30-50% of the usual dose.
CrCl (ml/min)Dosage Recommendation
<50per 1.48 m2: Dose reduction may be needed.


Intravenous
Heart failure
Adult: 100-600 mcg daily, depending upon desired digitalisation (usually performed over 2-4 days); larger doses are given in divided doses. Maintenance: Continue with 50-300 mcg daily by mouth in divided doses.
Elderly: Dose reduction may be required.
Renal impairment: Dialysis: Initially, 30-50% of the usual dose.
CrCl (ml/min)Dosage Recommendation
<50per 1.48 m2: Dose reduction may be needed.
Contraindications
Wolff-Parkinson-White syndrome or other evidence of an accessory pathway; hypertrophic obstructive cardiomyopathy.
Special Precautions
Severe pulmonary disease, hypoxia, myxoedema, acute MI, severe heart failure, acute myocarditis, chronic constrictive pericarditis, acute glomerulonephritis and CHF, idiopathic hypertrophic subaortic stenosis. IV admin in hypertensive patients. Incomplete AV block, especially in those with Adams-Stokes attacks. Increased carotid sinus sensitivity, frequent ventricular premature contractions or ventricular tachycardia. Withhold 1-2 days before elective cardioversion. Electrolyte disturbances, thyroid dysfunction. Elderly, premature infants, renal impairment. Not an appropriate form of therapy for any ventricular arrhythmia. Pregnancy.
Adverse Reactions
Nausea, vomiting, anorexia, diarrhoea, abdominal pain, headache, facial pain, fatigue, weakness, dizziness, drowsiness, disorientation, mental confusion, bad dreams, delirium, acute psychoses, hallucinations, convulsions, blurred vision, colour vision may be affected, gynaecomastia.
Potentially Fatal: Heart failure, supraventricular or ventricular arrhythmias, conduction defects.
Overdosage
Symptoms: Nausea, vomiting, anorexia, diarrhoea, abdominal pain, headache, facial pain, fatigue, weakness, dizziness, drowsiness, disorientation, mental confusion, bad dreams, delirium, acute psychoses, hallucinations, convulsions, blurred vision, colour vision may be affected, gynaecomastia. Management: Acute poisoning: Gastric lavage if patient presents within 1 hr of ingestion. Repeated doses of activated charcoal, colestyramine and colestipol may be given. Haemodialysis or peritoneal dialysis, and forced diuresis with furosemide have generally been ineffective. Antiarrhythmic treatment may be necessary. Correct hypokalaemia and other electrolyte disturbances. Massive poisoning: Reverse progressive hyperkalaemia. Soluble insulin with glucose may be given; if refractory, dialysis may be tried. Massive overdosage has been treated successfully with digoxin-specific antibody fragments.
Drug Interactions
Increased risk of additive bradycardia with diltiazem. Increased risk of digitalis toxicity with amphotericin B, carbenoxolone, corticosteroids. Increased CV adverse events with HRT. Reduced serum digoxin levels with rifampicin, colestyramine.
Potentially Fatal: Increased digitalis glycosides toxicity with potassium-depleting diuretics. Increased risk of cardiac arrhythmias with IV calcium.
Food Interaction
Many herbal preparations contain cardiac glycosides; additive effects with metildigoxin may possibly occur.
Action
Metildigoxin is a cardiac glycoside with positive inotropic activity.
Onset: 5-20 min.
Absorption: Rapidly and almost completely absorbed from the GI tract.
Metabolism: Hepatic demehylation to digoxin; reduced in patients with cirrhosis.
Excretion: Via urine (about 60% of dose; as unchanged drug and metabolites).
CIMS Class
ATC Classification
C01AA08 - metildigoxin ; Belongs to the class of digitalis glycosides. Used in the treatment of heart failure.
Disclaimer: This information is independently developed by CIMS based on metildigoxin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in